- Trials with a EudraCT protocol (53)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (1)
53 result(s) found for: Cervical Dysplasia.
Displaying page 1 of 3.
EudraCT Number: 2008-007763-16 | Sponsor Protocol Number: 1.0 | Start Date*: 2009-05-06 | ||||||||||||||||
Sponsor Name:Medizinische Universität Wien, Univ.Klinik f.Frauenheilkunde,Abt. f.Gynäkologie und Gyn.Onkologie | ||||||||||||||||||
Full Title: Topical Imiquimod in Treating Patients with Grade 2/3 Cervical Intraepithelial Neoplasia | ||||||||||||||||||
Medical condition: Grade 2/3 Cervical Intraepithelial Neoplasia | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||
Trial protocol: AT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2008-006208-52 | Sponsor Protocol Number: IFN005 | Start Date*: 2009-03-09 | |||||||||||
Sponsor Name:Helix BioPharma Cooperation | |||||||||||||
Full Title: Mono-centre, open-label study to investigate the multi-dose pharmacokinetics, efficacy and safety of Interferon alpha-2b Cream in women with a history of cytological diagnosed Pap IIID, with a con... | |||||||||||||
Medical condition: cervical dysplasia (CIN I or CIN II; Pap IIID in the history, confirmed HPV+ status) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-006946-24 | Sponsor Protocol Number: NV25025 | Start Date*: 2009-12-10 | ||||||||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | ||||||||||||||||||
Full Title: A randomized, double blind, placebo controlled, parallel group, multicenter study of the safety and response rate of 3 subcutaneously administered doses of 5x10E7pfu RO5217790 in patients with high... | ||||||||||||||||||
Medical condition: High grade cervical intraepithelial neoplasia grade 2 or 3 associated with High Risk HPV infection | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||
Trial protocol: DE (Prematurely Ended) FI (Completed) ES (Completed) BE (Completed) | ||||||||||||||||||
Trial results: Removed from public view |
EudraCT Number: 2010-023271-26 | Sponsor Protocol Number: MI-CI-C02 | Start Date*: 2011-02-01 | |||||||||||
Sponsor Name:Mithra Pharmaceuticals SA | |||||||||||||
Full Title: A randomized, double-blind, multi-centre, placebo controlled phase II clinical study to evaluate the efficacy, tolerance and safety of an aqueous gel containing 2% (w/w) of cidofovir, directly appl... | |||||||||||||
Medical condition: High Grade of Cervical Intraepithelial Neoplasia (CIN). | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-002247-23 | Sponsor Protocol Number: MITOCERV4 | Start Date*: 2020-01-29 | ||||||||||||||||
Sponsor Name:FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE | ||||||||||||||||||
Full Title: Single arm phase II study on Pembrolizumab in preneoplastic high grade HPV-related vulvar and cervical lesions | ||||||||||||||||||
Medical condition: Patients with pre neoplastic high grade HPV-related vulvar and cervical lesions | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||
Trial protocol: IT (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-000318-12 | Sponsor Protocol Number: MITOCERV3 | Start Date*: 2020-02-20 | |||||||||||
Sponsor Name:FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE | |||||||||||||
Full Title: MITO CERV 3:Phase II study on Carboplatin-Paclitaxel-Pembrolizumab in neoadjuvant treatment of locally advanced cervical cancer | |||||||||||||
Medical condition: Locally advanced cervical cancer. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-004721-40 | Sponsor Protocol Number: HPV-EU-001 | Start Date*: 2015-04-22 | |||||||||||
Sponsor Name:Genexine, Inc | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-controlled, Multi-Center, Phase 2 Clinical Trial to Evaluate the Efficacy and the Safety of GX-188E, a DNA-based Therapeutic Vaccine, Administered Intramuscularl... | |||||||||||||
Medical condition: Cervical Intraepithelial Neoplasia Grade 2 (CIN 2), Grade 2/3 (CIN 2/3) or Grade 3 (CIN3) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: EE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-001334-33 | Sponsor Protocol Number: HPV-003 | Start Date*: 2013-01-09 | |||||||||||
Sponsor Name:Inovio Pharmaceuticals, Inc. | |||||||||||||
Full Title: PHASE II PLACEBO-CONTROLLED STUDY OF VGX-3100, (HPV16 E6/E7, HPV18 E6/E7 DNA VACCINE) DELIVERED IM FOLLOWED BY ELECTROPORATION (EP) WITH CELLECTRA®-5P FOR THE TREATMENT OF BIOPSY-PROVEN CIN 2/3 OR ... | |||||||||||||
Medical condition: Cervical Intraepithelial Neoplasia (CIN) 2/3 or 3 | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: EE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-004235-36 | Sponsor Protocol Number: EWO-ISO-2017/2 | Start Date*: 2018-09-27 |
Sponsor Name:Ewopharma AG | ||
Full Title: A phase 4, randomized, open label multi-centre clinical study to evaluate efficacy of Isoprinosine® in female subjects with low-grade cervical dysplasia caused by HrHPV. | ||
Medical condition: Low-grade cervical dysplasia caused by HrHPV | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: CZ (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-003177-42 | Sponsor Protocol Number: COHEAHR-WP4 | Start Date*: 2014-10-10 | ||||||||||||||||
Sponsor Name:Catalan Institute of Oncology | ||||||||||||||||||
Full Title: Multinational study assessing the acceptability and determinants of compliance to HPV vaccination to women in screening ages 30 to 45 years | ||||||||||||||||||
Medical condition: Cervical cancer | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Female | |||||||||||||||||
Trial protocol: DK (Completed) ES (Completed) BE (Completed) FI (Completed) SI (Completed) NL (Completed) SE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2020-001169-34 | Sponsor Protocol Number: HPV_Elimination | Start Date*: 2021-03-24 | ||||||||||||||||
Sponsor Name:Region Stockholm [...] | ||||||||||||||||||
Full Title: Concomitant HPV vaccination and HPV screening for rapid elimination of HPV infection and cervical cancer in Sweden | ||||||||||||||||||
Medical condition: HPV infection and related diseases, such as cervical intraepithelial neoplasia grade 2 and 3 and cervical cancer. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Female | |||||||||||||||||
Trial protocol: SE (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-003507-19 | Sponsor Protocol Number: HOPE9 | Start Date*: 2020-09-10 | |||||||||||||||||||||
Sponsor Name:AZIENDA USL TOSCANA NORD OVEST | |||||||||||||||||||||||
Full Title: “Phase III, randomized, double-blind, placebo-controlled multicenter study to evaluate the efficacy of pre-surgical HPV 9-valent vaccination in women treated with electrosurgical excision with diat... | |||||||||||||||||||||||
Medical condition: Prevention of recurrence after a first episode of high-grade cervical intraepithelial neoplasia (CIN2 +) up to initially invasive cervical cancer (FIGO IA1) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||||||||||||
Trial protocol: IT (Trial now transitioned) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-000269-42 | Sponsor Protocol Number: 1-23-456 | Start Date*: 2022-06-08 | |||||||||||
Sponsor Name:Randers Regional Hospital, Department of Gynecology and Obstetrics | |||||||||||||
Full Title: Improving diagnostics in cervical dysplasia | |||||||||||||
Medical condition: Abnormal cervical cells | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: DK (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-003944-23 | Sponsor Protocol Number: UFK-HEF 5 | Start Date*: 2005-04-20 |
Sponsor Name:Medical University of Vienna | ||
Full Title: Acetyl salicylic acid in the treatment of patients with positive margins after surgery for cervical dysplasia grade II-III: A phase II trial | ||
Medical condition: Cervical intraepithelial neoplasia grade II/III with positive margin after surgery | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: AT (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2008-005987-15 | Sponsor Protocol Number: The Triple P study | Start Date*: 2009-10-22 | |||||||||||
Sponsor Name:AMC Amsterdam | |||||||||||||
Full Title: Preventing preterm birth: Costs and effects of screening of healthy women with a singleton pregnancy for a short cervical length. | |||||||||||||
Medical condition: Preterm birth with healthy singleton pregnancies | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-000456-15 | Sponsor Protocol Number: 3518 | Start Date*: 2015-05-19 | |||||||||||
Sponsor Name:Kings College London [...] | |||||||||||||
Full Title: The prevention of pre-term birth in women who develop a short cervix. A multi-centre randomised controlled trial to compare three treatments; cervical cerclage, cervical pessary and vaginal proges... | |||||||||||||
Medical condition: Short Cervix in Pregnancy | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-019657-18 | Sponsor Protocol Number: 1.0 | Start Date*: 2010-06-04 | ||||||||||||||||
Sponsor Name:Medizinische Universität Wien, Univ.Klinik f.Frauenheilkunde,Abt. f.Gynäkologie und Gyn.Onkologie | ||||||||||||||||||
Full Title: Topical Imiquimod in Treating Patients with Persistent HPV-Infection after Surgical or Radiation Treatment of Cervical Cancer | ||||||||||||||||||
Medical condition: Patients with positive high risk HPV-test 6 months after surgical or radiation treatment for cervical cancer are eligible for this trial. After signing informed consent patients are randomized to H... | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||
Trial protocol: AT (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2008-004604-31 | Sponsor Protocol Number: PCCE201/08 | Start Date*: 2008-10-28 | |||||||||||
Sponsor Name:Photocure ASA | |||||||||||||
Full Title: A randomized phase II dose-finding study of hexaminolevulinate (HAL) photodynamic therapy (PDT) in patients with low-grade cervical intraepithelial neoplasia. | |||||||||||||
Medical condition: Low grade cervical intraepithelial neoplasia (CIN) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: DE (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-002035-26 | Sponsor Protocol Number: 115411 | Start Date*: 2011-10-21 | |||||||||||||||||||||
Sponsor Name:GlaxoSmithKline Biologicals | |||||||||||||||||||||||
Full Title: A Phase IIIb observer-blind, randomized, multicentre primary immunization study to evaluate the immunogenicity and safety of GSK Biologicals’ HPV-16/18 L1 VLP AS04 vaccine and Merck's Quadrivalent ... | |||||||||||||||||||||||
Medical condition: Cervarix is indicated in females from 10 years of age onwards for the prevention of persistent infection, premalignant cervical lesions and cervical cancer (squamous-cell carcinoma and adenocarcino... | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Female | ||||||||||||||||||||||
Trial protocol: FR (Completed) SE (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2016-002761-63 | Sponsor Protocol Number: HPV-301 | Start Date*: 2018-04-16 | ||||||||||||||||
Sponsor Name:Inovio Pharmaceuticals, Inc. | ||||||||||||||||||
Full Title: A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF VGX-3100 DELIVERED INTRAMUSCULARLY FOLLOWED BY ELECTROPORATION WITH CELLECTRA™ 5PSP FOR THE TREATMENT OF HPV-16 AND/OR H... | ||||||||||||||||||
Medical condition: HPV-16 AND/OR HPV-18 RELATED HIGH GRADE SQUAMOUS INTRAEPITHELIAL LESIONS (HSIL) OF THE CERVIX | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) LT (Completed) FI (Completed) DE (Completed) CZ (Prematurely Ended) ES (Completed) PT (Completed) PL (Completed) SK (Completed) BE (Completed) NL (Ongoing) EE (Completed) IT (Completed) | ||||||||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
